Actinium Pharmaceuticals, Inc.
ATNM
$1.29
-$0.105-7.55%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.83% | 3.59% | -21.22% | -20.70% | -41.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.00% | -12.19% | -20.61% | -17.15% | -7.68% |
| Operating Income | 27.44% | 12.19% | 20.61% | 17.15% | 8.40% |
| Income Before Tax | 28.66% | 12.87% | 25.22% | 21.45% | 12.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.66% | 12.87% | 25.22% | 21.45% | 12.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.66% | 12.87% | 25.22% | 21.45% | 12.43% |
| EBIT | 27.44% | 12.19% | 20.61% | 17.15% | 8.40% |
| EBITDA | 27.57% | 12.38% | 20.76% | 17.72% | 8.44% |
| EPS Basic | 37.28% | 24.11% | 34.87% | 27.61% | 18.63% |
| Normalized Basic EPS | 37.32% | 24.13% | 34.87% | 27.61% | 18.58% |
| EPS Diluted | 37.28% | 24.11% | 34.87% | 27.61% | 18.63% |
| Normalized Diluted EPS | 37.32% | 24.13% | 34.87% | 27.61% | 18.58% |
| Average Basic Shares Outstanding | 13.77% | 14.83% | 14.82% | 8.52% | 7.59% |
| Average Diluted Shares Outstanding | 13.77% | 14.83% | 14.82% | 8.52% | 7.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
